The National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) Federal Grant Program, awarded a $2,552,654.85 Project Grant to Vanderbilt University Medical Center. The grant, awarded on January 1, 2025, will fund a 5-year project to systematically screen and validate drug repurposing candidates for Alzheimer's disease and related dementias (AD/ADRD). The key products and services to be delivered include: Integrating genetics, transcriptomics, literature, and clinical data to...
This federal Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $787,103 to Vanderbilt University to develop a novel siRNA-lipid conjugate technology called "siRNA-EG18" for targeted gene silencing in brain myeloid cells as a potential treatment for Alzheimer's disease. The project aims to comprehensively analyze siRNA-EG18's ability to silence key Alzheimer's-related genes like CD33 in myeloid cells, including under aging and...
The National Institute on Aging (NIA), part of the Department of Health and Human Services National Institutes of Health, awarded a $3.37 million Project Grant to The University of Texas at Arlington to develop an individualized deep connectome framework for Alzheimer's disease and related dementias (ADRD) analysis. The three-year grant, awarded on August 18, 2022 under the NIA's Aging Research program (CFDA 93.866), will support research to discover and identify individualized...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,946,385.00 to Vanderbilt University to develop novel analytic approaches to dissect cell-cell communication among microglia, astrocytes, and neurons, and understand how these communications are dysregulated during Alzheimer's disease (AD) progression. The project aims to: 1) develop network-based models and statistical methods to identify cell-cell communications linked to AD pathogenesis, 2)...
This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...
The National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) Federal Grant Program, awarded a $2,763,221 project grant to Cedars-Sinai Medical Center. The 5-year grant, effective September 1, 2024, will support research to examine the impact of physician, hospital, and skilled-nursing facility factors related to geriatric care on days spent at home among persons with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The study aims to determine how...
The National Institute on Aging (NIA) awarded a $125,896 Project Grant under the Aging Research program (CFDA 93.866) to The Washington University in St. Louis to conduct research on Alzheimer's disease (AD) risk and resilience pathways. The project aims to perform deep molecular characterization of AD genetic risk factors and protective mechanisms using state-of-the-art single-cell multi-omic analyses of healthy and AD human brain tissue, as well as transgenic AD mouse models. Key objectives...
This Project Grant award, totaling $770,558, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The award will fund a research project titled "NEUROIMAGE-GENOMIC FINGERPRINTS FOR SUBTYPING AND PREDICTION OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA" at Wake Forest University Health Sciences over a period of 5 years, from July 1, 2025 to March 31, 2030. The project aims to establish connections between Alzheimer's disease-related genomic...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant under the Aging Research (CFDA 93.866) federal grant program to The Leland Stanford Junior University. The grant titled "Combinatorial Perturbation with Multi-Omics Readout to Dissect Etiology of Alzheimer's Disease Using Stem Cell and In Vivo Models" aims to develop innovative tools and methodologies to study the complex genetic interactions underlying Alzheimer's disease pathogenesis. Key products include...
The National Institute on Aging (NIA) awarded a $972,000 Project Grant under the Aging Research (CFDA 93.866) program to Vanderbilt University Medical Center (VUMC). The grant, which runs from August 2024 to May 2029, will support research to characterize the genetic architecture underlying the age of onset of amyloid positivity in Alzheimer's disease. The project will leverage advanced imaging and AI techniques to analyze amyloid PET data from over 16,000 participants, with the goal of identifying novel genetic drivers of Alzheimer's disease progression. The research aims to provide insights into the heterogeneity of Alzheimer's disease onset and advance the development of precision interventions. VUMC will collaborate with Dr. Timothy Hohman, the primary mentor, and receive training from experts in imaging genetics, genomic analysis, and geriatrics to position the researcher as a leader in the intersection of imaging and genetics for Alzheimer's disease.